Abstract: Described herein are methods for predicting a benefit from inclusion of taxane in a chemotherapy regimen in a patient suffering from or at risk of developing recurrent neoplastic disease, in particular breast cancer. Said method includes the steps of determining the expression levels of the marker genes S100P and PCSK6 and mathematically combining the expression level values to yield a combined score and comparing said combined score to a reference-value, wherein a high combined score is indicative of a benefit from including a taxane in a chemotherapy regimen of said patient and a low combined score is indicative of not having a benefit from including a taxane in a chemotherapy regimen.

Abstract: Described herein are methods for predicting a benefit from inclusion of taxane in a chemotherapy regimen in a patient suffering from or at risk of developing recurrent neoplastic disease, in particular breast cancer. Said method includes the steps of determining the expression levels of the marker genes S1OOP and PCSK6 and mathematically combining the expression level values to yield a combined score and comparing said combined score to a reference-value, wherein a high combined score is indicative of a benefit from including a taxane in a chemotherapy regimen of said patient and a low combined score is indicative of not having a benefit from including a taxane in a chemotherapy regimen.

Abstract: A method predicts the residual risk of recurrence after a taxane-free chemotherapy, and the benefit from inclusion of taxane in a chemotherapy regimen in a patient suffering from or at risk of developing recurrent breast cancer. From determination of expression levels of the genes UBE2C, KIF20A, PTGER3, OSBPL1A, CYP27A1, IGKC, in a tumor sample a prognostic score is determined by mathematically combining the expression level values. The prognostic score is compared to thresholds, classifying the patient in three outcome groups. The expression levels of three genes STC1, PCSK6, S100P in the tumor sample are determined, and the expression level values for STC1, PCSK6 and S100P are mathematically combined to yield a predictive combined score, whereas a high predictive combined score generally indicates an increased likelihood of benefit from inclusion of taxane in a chemotherapy regimen in a patient classified to poor and/or intermediate outcome group.

Abstract: A method for predicting a benefit from inclusion of taxane in a chemotherapy regimen in a patient suffering from or at risk of developing recurrent neoplastic disease, in particular breast cancer.